Hims & Hers Health (HIMS) EBITDA (2019 - 2026)

Hims & Hers Health (HIMS) has 8 years of EBITDA data on file, last reported at -$78.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 235.28% year-over-year to -$78.3 million; the trailing twelve-month figure through Mar 2026 stood at -$30.6 million (down 127.85% YoY), and the FY2025 full-year result was $105.6 million, up 70.61% from the prior year.
• EBITDA retreated to -$78.3 million in Q1 2026, from $9.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $57.9 million in Q1 2025 to a low of -$78.3 million in Q1 2026.
• A 5-year average of -$526882.4 and a median of -$400000.0 in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 4749.0% in 2024 and sank 235.28% in 2026, its largest moves.
• Tracing HIMS's EBITDA over 5 years: stood at -$11.6 million in 2022, then surged by 96.55% to -$400000.0 in 2023, then jumped by 4749.0% to $18.6 million in 2024, then sank by 50.6% to $9.2 million in 2025, then tumbled by 952.63% to -$78.3 million in 2026.
• Business Quant data shows HIMS's EBITDA at -$78.3 million in Q1 2026, $9.2 million in Q4 2025, and $11.8 million in Q3 2025.